Abstract
The antiarrhythmic effects of bisaramil were examined in canine models of digitalis-, adrenaline- and two-stage coronary ligation- induced arrhythmia. Bisaramil (0.3–1.5 mg/kg i.v.) suppressed all the arrhythmias. The antiarrhythmic plasma concentration (IC 50) for arrhythmias induced by digitalis, adrenaline, and 24 h two-stage coronary ligation were 0.11, 0.81, and 0.75 μg/ml, respectively. Bisaramil is a potent class I agent, judging from its low antiarrhythmic plasma concentrations. Oral bisaramil (10 mg/kg) also suppressed 24-h coronary ligation-induced arrhythmia. These results indicate that bisaramil may be a useful drug for the treatment of various clinical ventricular arrhythmias.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
